➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
McKesson
Dow
AstraZeneca

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,925,151

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,925,151
Title:Cladribine regimen for treating multiple sclerosis
Abstract: The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
Inventor(s): Brentzel, Jr.; H. James (Marshfield, MA), Lopez-Bresnahan; Maria (Lincoln, MA), Ammoury; Nazih (Prevessin-Moens, FR)
Assignee: MERCK SERONO SA (Coinsins, Vaud, CH)
Application Number:12/301,083
Patent Claims:1. A method of treating patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis with interferon beta-1a, interferon beta-1b, or glatiramer acetate, said method comprising administering IFN-.beta. in combination with orally administered Cladribine to a patient refractory to at least one conventional therapy for multiple sclerosis with interferon beta-1a, interferon beta-1b, or glatiramer acetate according to the following sequential steps: (i) an induction period wherein Cladribine is administered and wherein the total dose of Cladribine reached at the end of the induction period is from about 1.5 mg/kg to about 3.5 mg/kg; (ii) a Cladribine-free period wherein no Cladribine is administered; (iii) a maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); and (iv) a Cladribine-free period wherein no Cladribine is administered; wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year and: a) the duration of the induction period (i) is about 4 months and the duration of the Cladribine-free period (ii) is about 8 months; b) the duration of the induction period (i) is about 2 months and the duration of the Cladribine-free period (ii) is about 10 months; or c) the duration of the induction period (i) is up to 4 months and the duration of the Cladribine-free period (ii) is up to 8 months.

2. The method according to claim 1, wherein the total dose of Cladribine reached at the end of the induction period (i) is from about 1.7 mg/kg to about 3.5 mg/kg.

3. The method according to claim 1, wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year and the total dose of Cladribine reached at the end of this year of treatment is about 1.7 mg/kg or about 3.5 mg/kg.

4. The method according to claim 1, wherein the combined duration of the maintenance period (iii) with the Cladribine-free period (iv) is about 1 year.

5. The method according to claim 4, wherein the duration of the maintenance period (iii) is about 2 months and the duration of the Cladribine-free period (iv) is about 10 months.

6. The method according to claim 4, wherein the combined duration of the maintenance period (iii) with the Cladribine-free period (iv) is about 1 year and the total dose of Cladribine administered during this year of treatment is about 1.7 mg/kg.

7. The method according to claim 1, wherein the combined duration of the induction period (i), the Cladribine-free period (ii), the maintenance period (iii) and the Cladribine-free period (iv) is about 2 years.

8. The method according to claim 7, wherein: the duration of the induction period (i) is about 4 months, the duration of the Cladribine-free period (ii) is about 8 months, the duration of the maintenance period (iii) is about 2 months and the duration of the Cladribine-free period (iv) is about 10 months; or the duration of the induction period (i) is about 2 months, the duration of the Cladribine-free period (ii) is about 10 months, the duration of the maintenance period (iii) is about 2 months and the duration of the Cladribine-free period (iv) is about 10 months.

9. The method according to claim 7, wherein the combined duration of the induction period (i) and the Cladribine-free period (ii) is about 1 year, the combined duration of the maintenance period (iii) and the Cladribine-free period (iv) is about 1 year, the total dose of Cladribine administered during the first year of treatment is about 1.7 mg/kg and the total dose of Cladribine administered during the second year of treatment is about 1.7 mg/kg.

10. The method according to claim 7, wherein the combined duration of the induction period (i) and the Cladribine-free period (ii) is about 1 year, the combined duration of the maintenance period (iii) and the Cladribine-free period (iv) is about 1 year, the total dose of Cladribine administered during the first year of treatment is about 3.5 mg/kg and the total dose of Cladribine administered during the second year of treatment is about 1.7 mg/kg.

11. The method according to claim 1, wherein steps (iii) to (iv) are repeated one, two or three times.

12. The method according to claim 1, wherein the bioavailability of Cladribine is about 40%.

13. The method according to claim 1, wherein the total effective dose of Cladribine reached at the end of the induction period (i) is about 0.7 mg/kg or about 1.4 mg/kg.

14. The method according to claim 1, wherein the total effective dose of Cladribine administered during the maintenance period (iii) is about 0.7 mg/kg.

15. The method according to claim 1, wherein Cladribine is administered from 4 to 7 days per month during the induction period (i).

16. The method according to claim 15, wherein Cladribine is administered from day 1 to day 5 each month during the induction period (i).

17. The method according to claim 15, wherein Cladribine is administered at a daily dose of about 0.175 mg/kg during the induction period (i).

18. The method according to claim 1, wherein Cladribine is administered from 4 to 7 days per month during the maintenance period (iii).

19. The method according to claim 18, wherein Cladribine is administered from day 1 to day 5 each month during the maintenance period (iii).

20. The method according to claim 18, wherein Cladribine is administered at a daily dose of about 0.175 mg/kg during the maintenance period (iii).

21. The method according to claim 1, wherein IFN-beta is administered simultaneously, separately or sequentially with oral Cladribine.

22. The method according to claim 21, wherein IFN-beta is administered simultaneously with oral Cladribine.

23. The method according to claim 22, wherein IFN-beta is administered during the induction period (i), the maintenance period (iii) and the Cladribine-free periods (ii) and (iv).

24. The method according to claim 23, wherein IFN-beta is administered before the induction period (i), during the induction period (i), during the maintenance period (iii), during the Cladribine-free periods (ii) and (iv) and after the Cladribine-free period (iv).

25. The method according to claim 21, wherein the IFN-beta is administered subcutaneously or intramuscularly.

26. The method according to claim 25, wherein the IFN-.beta. is administered at 44 mcg subcutaneously three times a week.

27. The method according to claim 1, wherein the conventional therapy is selected from the group consisting of: treatment with treatment with Glatiramer Acetate, treatment with natalizumab, and treatment with Mitoxantrone.

28. The method according to claim 1, wherein the conventional therapy is treatment with beta interferon.

29. The method according to claim 1, wherein the refractory patients to be treated have experienced at least one relapse in spite of receiving at least one conventional therapy.

30. The method according to claim 29, wherein the at least one relapse occurred during the year prior the beginning of the treatment.

31. The method according to claim 30, wherein the patients to be treated have experienced at least one relapse during the year preceding the beginning of the treatment and have been treated with 12 MIU (44 mcg) of IFN-.beta. three times a week.

32. The method according to claim 1, wherein the refractory patients to be treated have acquired enhanced lesion number or enhanced brain lesion volume in the CNS as detected using methods such as MRI technique.

33. The method according to claim 32, wherein the enhanced lesion number or enhanced brain lesion volume occurred during the year prior to the beginning of the treatment.

34. The method according to claim 33, wherein the patients to be treated have acquired enhanced lesion number or enhanced brain lesion volume in the CNS during the year.

35. The method according to claim 1, wherein the refractory patients to be treated have experienced at least one relapse and have developed increasing disability because of progressive forms of the disease.

36. The method according to claim 1, wherein the refractory patients to be treated are suffering from worsening MS, secondary progressive MS, progressive remitting MS or worsening relapsing-remitting MS.

37. The method according to claim 1, wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year and the duration of the induction period (i) is about 2 months and the duration of the Cladribine-free period (ii) is about 10 months.

38. The method according to claim 1, wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year and the duration of the induction period (i) is up to 4 months and the duration of the Cladribine-free period (ii) is up to 8 months.

39. The method according to claim 1, wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is 1 year and the duration of the induction period (i) is 4 months and the duration of the Cladribine-free period (ii) is 8 months.

40. The method according to claim 1, wherein said IFN-.beta. is IFN-.beta.1a or IFN-.beta.1b.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06114537May 24, 2006
PCT Information
PCT FiledMay 23, 2007PCT Application Number:PCT/EP2007/055013
PCT Publication Date:November 29, 2007PCT Publication Number:WO2007/135172

Details for Patent 9,925,151

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial MERCK SERONO SA (Coinsins, Vaud, CH) 2026-05-24 RX Orphan search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial MERCK SERONO SA (Coinsins, Vaud, CH) 2026-05-24 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial MERCK SERONO SA (Coinsins, Vaud, CH) 2026-05-24 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial MERCK SERONO SA (Coinsins, Vaud, CH) 2026-05-24 RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial MERCK SERONO SA (Coinsins, Vaud, CH) 2026-05-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKesson
Mallinckrodt
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.